G6PD 蛋白, Human (HEK293, His)

The G6PD protein is a rate-limiting enzyme in the oxidative pentose phosphate pathway located in the cytosol, which is crucial for the catabolism of carbohydrates in glycolysis. The primary function of G6PD is to provide reducing power in the form of NADPH and generate pentose phosphates, helping the cell resist oxidative stress and regulate metabolic rates. Additionally, the activity of G6PD is associated with cancer progression. The G6PD protein (Human, HEK293, His) is a recombinant G6PD protein expressed in HEK293 cells, with a C-terminal His tag, and consists of 514 amino acids (A2-L515) ^{[1][2][3][4][5][6][7]}.

G6PD 是葡萄糖代谢中磷酸戊糖途径的第一个酶。通过调控磷酸戊糖途径，G6PD 可以维持细胞内还原型谷胱甘肽的水平，帮助细胞抵抗氧化应激。G6PD 蛋白对于保护红细胞免受氧化应激至关重要，缺乏此酶可能导致溶血、新生儿黄疸以及蚕豆病^[1][2]。
G6PD 活性与卵母细胞发育密切相关，随着卵母细胞完成其生长阶段，G6PDH 的活性会显著下降，表明其在细胞早期发育阶段中起到关键作用^[3]。
G6PD 在多种癌症中上调，并与肿瘤发育及肿瘤对化疗的耐药性有关，例如，G6PD 表达上调可以抑制骨肉瘤 (OS) 组织和细胞系 (MG-63、SaoS-2、SJSA-1、G-292) 中抑制由氧化应激引起的细胞凋亡。G6PD 还可以作为一种血管生成因子，促进血管生成，为肿瘤细胞提供营养，并促进肿瘤细胞的生长。G6PD 有望作为抑制肿瘤生长的靶点^[4]。

沉默 G6PD (Human) (通过 siRNA 转染 A2780/CDDP 细胞来沉默) 可通过诱导卵巢癌顺铂耐药细胞株 A2780/CDDP (通过低浓度加量持续诱导法构建) 中铁死亡而增强其对顺铂的敏感性^[5]。
G6PD (Human) 活性可被 Macrolepiota procera 提取物抑制，IC₅₀ 值为 0.853 μg/mL，G6PD 活性的降低可抑制 A549 肺癌细胞生长^[6]。

G6PD 活性下降会在 G6PD 缺陷小鼠模型中激活蛋白激酶 C (PKC) 和 NF-κB，增加肾脏氧化应激和白蛋白尿^[7]。

Measured by its ability to dehydrogenate 1mM glucose-6-phosphate. that incubate at room temperature in kinetic mode for 5 minutes. The specific activity is 14469.453-15675.24 pmol/min/μg.

Human

HEK293

C-6*His

P11413-1 (A2-L515)

2539  [NCBI]

AEQVALSRTQVCGILREELFQGDAFHQSDTHIFIIMGASGDLAKKKIYPTIWWLFRDGLLPENTFIVGYARSRLTVADIRKQSEPFFKATPEEKLKLEDFFARNSYVAGQYDDAASYQRLNSHMNALHLGSQANRLFYLALPPTVYEAVTKNIHESCMSQIGWNRIIVEKPFGRDLQSSDRLSNHISSLFREDQIYRIDHYLGKEMVQNLMVLRFANRIFGPIWNRDNIACVILTFKEPFGTEGRGGYFDEFGIIRDVMQNHLLQMLCLVAMEKPASTNSDDVRDEKVKVLKCISEVQANNVVLGQYVGNPDGEGEATKGYLDDPTVPRGSTTATFAAVVLYVENERWDGVPFILRCGKALNERKAEVRLQFHDVAGDIFHQQCKRNELVIRVQPNEAVYTKMMTKKPGMFFNPEESELDLTYGNRYKNVKLPDAYERLILDVFCGSQMHFVRSDELREAWRIFTPLLHQIELEKPKPIPYIYGSRGPTEADELMKRVGFQYEGTYKWVNPHKL

Approximately 55-62 kDa

Greater than 95% as determined by reducing SDS-PAGE.

溶液.

Supplied as a 0.2 μm filtered solution of 20mM Citrate, 15% Trehalose, 150mM NaCl, 0.05% Tween 80, pH5.5 or PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

N/A.

Stored at -80°C for 1 year. It is stable at -20°C for 3 months after opening. It is recommended to freeze aliquots at -80°C for extended storage. Avoid repeated freeze-thaw cycles.

Shipping with dry ice.

• [1]. Harcke SJ, et al. G6PD deficiency: An update. JAAPA. 2019 Nov;32(11):21-26.  [Content Brief]

  [2]. Blanc L, et al. General considerations of hemolytic diseases, red cell membrane, and enzyme defects[M]//Lanzkowsky's Manual of Pediatric Hematology and Oncology. Academic Press, 2022: 125-149.

  [3]. https://pubmed.ncbi.nlm.nih.gov/1242707/

  [4]. An F, Chang W, Song J, Zhang J, Li Z, Gao P, Wang Y, Xiao Z, Yan C. Reprogramming of glucose metabolism: Metabolic alterations in the progression of osteosarcoma. J Bone Oncol. 2024 Jan 4;44:100521.  [Content Brief]

  [5]. 陈朝梅, 等. 沉默 G6PD 对卵巢癌细胞顺铂敏感性的影响及其作用机制[J]. 中国癌症防治杂志, 2022, 14(3): 274-280.

  [6]. Zara R, et al. Identification of Macrolepiota procera extract as a novel G6PD inhibitor for the treatment of lung cancer. Saudi J Biol Sci. 2022 May;29(5):3372-3379.  [Content Brief]

  [7]. Xu Y, et al. Glucose-6-phosphate dehydrogenase-deficient mice have increased renal oxidative stress and increased albuminuria. FASEB J. 2010 Feb;24(2):609-16.  [Content Brief]